Following a priority review of these data, the FDA approved revumenib as a treatment for KMT2A-rearranged acute leukemias in the relapsed or refractory setting while awaiting the final analysis for the NPM1-mutated AML subset (Table 1). The gene discussed is KMT2A; the disease is acute myeloid leukemia.